Showing 491-500 of 591 results for "".
- Galderma to Begin Two Phase III Restylane Trialshttps://practicaldermatology.com/news/galderma-to-begins-two-phase-iii-restylane-trials/2458679/Galderma is set to initiate a pivotal Phase III trial on Restylane® Lyft for hand augmentation and another that will look to the safety of Restylane® Silk when ad
- Interferon Not Beneficial for Most Stage III Melanomahttps://practicaldermatology.com/news/interferon-not-beneficial-for-most-stage-iii-melanoma/2458703/Most stage III melanoma patients do not benefit from treatment with interferon, according to final results for the Sunbelt Melanoma Trial, published online in the Jour
- Alphaeon's Botulinum Toxin Meets Primary Endpoints in Two Phase III Trialshttps://practicaldermatology.com/news/alphaeons-botulinum-toxin-meets-primary-endpoints-in-two-phase-iii-trials/2458615/Alphaeon’s DWP-450 botulinum toxin type A achieved it primary endpoints in two Phase III trials reported at the American Society of Aesthetic Plastic Surgery meeting in Las Vegas. In the two phase III randomized, multi-center, placebo-controlled, double blind tria
- Secukinumab Phase III Data Confirm Significant Efficacy in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/secukinumab-phase-iii-data-confirm-significant-efficacy-in-patients-with-psoriatic-arthritis/2458858/Results from the Phase III FUTURE 1 study for secukinumab in psoriatic arthritis (PsA) were published online in The New England Journal of Medicine (NEJM). Secukinumab is the first interleukin-17A (IL-17A) antagonist to demonstrate efficacy in a Phase III
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,
- Genentech Initiates Phase III Trial of Rituximab in Pemphigus Vulgarishttps://practicaldermatology.com/news/genentech-initiates-phase-iii-trial-of-rituximab-in-pemphigus-vulgaris/2458885/Genentech has initiated a Phase III clinical trial investigating the use of Rituxan (rituximab) in patients with pemphigus vulgaris (PV). The aim of the PEMPHIX study is to determin
- A Pivotal Phase III Gevokizumab Study is Initiated in Patients With Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20141104-a_pivotal_phase_3_gevokizumab_study_is_initiated_in_patients_with_pyoderma_gangrenosum/2459074/The Phase III gevokizumab study in patients with active pyoderma gangrenosum, a rare neutrophilic dermatosis of expanding necrotic skin ulcers, is open for patient enrollment. The objective of the study is to assess the efficacy and safety of gevokizumab in treating the active ulc
- Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase III Psoriasis Studieshttps://practicaldermatology.com/news/20140822-lillys_ixekizumab_superior_to_etanercept_and_placebo_in_phase_iii_psoriasis_studies/2459137/Eli Lilly and Company's ixekizumab was found to be statistically superior to etanercept and placebo on all skin clearance measures in pivotal, Phase III UNCOVER studies in moderate-to-severe plaque psoriasis. "These data are important for people suffer
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P
- Novartis Announced Positive Phase III Psoriasis Results for Secukinumabhttps://practicaldermatology.com/news/20131021-novartis_announced_positive_phase_iii_psoriasis_results_for_secukinumab/2459432/Novartis announced results from its head-to-head Phase III FIXTURE study showing secukinumab (AIN457), an interleukin-17A (IL-17A) inhibitor, was significantly superior to etanercept (Enbrel) in moderate-to-severe